The utility of antibody-dependent cellular cytotoxicity (ADCC) for eliminating HIV-1-infected cells is of much interest for the design of both prophylactic vaccines for HIV-1 prevention and therapeutics to eliminate latently infected cells following reactivation. Significant research has been conducted to understand the antibody specificities involved in anti-HIV-1 ADCC responses. Perhaps equally important as the identity of the antibodies mediating these responses are factors regulating the ability of ADCC effector cells, in particular, natural killer (NK) cells, to respond to antibody-coated target cells. Indeed, a plethora of activating and inhibitory receptors expressed on the surface of NK cells might act in conjunction with CD16 to influence ADCC. As the expression of NKG2D and its ligands has been linked to HIV-1 disease progression, we evaluated if signals through NKG2D were involved in anti-HIV-1 ADCC. Utilizing assays measuring cytolysis, we provide the first data implicating NKG2D in antibody-dependent NK cell responses against a target cell line either pulsed with gp120 or infected with HIV-1. These observations are highly significant for understanding antibody-dependent NK cell responses against HIV-1 and might be useful for optimizing prophylactics and therapeutics aiming to utilize antibodies and optimally functional NK cells to control HIV-1.
Introduction

A
prophylactic vaccine is needed to slow the global burden of new HIV-1 infections. Traditional attempts to design such a vaccine have focused heavily on the induction of cytotoxic T lymphocytes (CTL) and/or broadly neutralizing antibodies (BnAbs). Given that clinical trials of CTLbased vaccines have failed and that current vaccine protocols are unable to elicit BnAbs, novel vaccine concepts are required. [1] [2] [3] The RV144 vaccine trial in Thailand represented the first HIV-1 vaccine to offer detectable protection against HIV-1 acquisition, providing a modest 31% efficacy. 4 Postvaccination analyses revealed that the vaccine did not induce BnAbs or robust CTL responses; instead the major correlate of protection was IgG capable of binding the V1V2 region of the HIV-1 envelope. [4] [5] [6] Further analyses revealed an association between protection and the ability of IgG to mediate antibody-dependent cellular cytotoxicity (ADCC). 5 This putative protective role for ADCC, however, was only observed when individuals exhibited low plasma levels of antiviral IgA, which can compete with IgG for epitope binding and block ADCC. 5, 7 The postvaccination analyses of the RV144 trial collectively suggest that non-neutralizing antibodydependent effector functions, such as ADCC, might represent a novel avenue for HIV-1 vaccine research.
Designing vaccines to utilize ADCC requires not only an understanding of the characteristics of ideal antibody responses but also an understanding of the effector cells that exploit induced antibodies to mediate ADCC. Natural killer (NK) cells and monocytes are the major mediators of anti-HIV-1 ADCC, but the response can also be mediated to a lesser degree by neutrophils. 8 The role of NK cells is particularly interesting, as these cells express a plethora of activating and inhibitory receptors, in addition to the activating CD16/FccRIIIa receptor for the IgG constant region. 9 These additional activating and inhibitory receptors can act in conjunction with CD16 to influence the ability of the NK cell to mediate antibody-dependent functions. Indeed, ligation of inhibitory killer immunoglobulin-like receptors by their major histocompatibility complex class I (MHC-I or HLA-I) ligands can inhibit ADCC triggered by anti-HIV-1 and therapeutic monoclonal antibodies. 10, 11 Others and we, however, have reported that this inhibition can be at least partially overcome upon antibody-dependent NK cell activation. 10, [12] [13] [14] In addition to evidence implicating signals from inhibitory receptors, antibody-mediated NK cell receptor crosslinking data have recently been published to suggest that ligation of certain activating receptors, including NKG2D and 2B4, can synergize with CD16 ligation to enhance NK cell calcium flux. 15 The putative role of NKG2D in enhancing CD16-mediated NK cell responses is of particular interest in the context of antibody-dependent anti-HIV-1 NK cell responses. Ligands of the NKG2D receptor are upregulated on HIV-1-infected cells by the viral Vpr protein, and NKG2D signaling has been implicated in the direct cytolysis of HIV-1-infected target cells by NK cells. [16] [17] [18] Furthermore, heightened levels of NKG2D expression on NK cells from HIV-1-infected individuals are associated with lower viral load set point and lower viral loads in long-term nonprogressors. 19 Further studies have revealed that HIV-1 may be able to evade NKG2D-mediated NK cell responses through Nef-mediated downregulation of NKG2D ligands or through Vpu-mediated downregulation of the NTB-A coactivation ligand. 20, 21 In addition, matrix-metalloproteinases (MMPs) produced in HIV-1-infected cells are able to cleave NKG2D ligands from the surface of infected cells, which results in the downregulation of NK cell NKG2D on binding of soluble receptors. 22, 23 Collectively, much evidence implicates NKG2D in NK cell recognition of HIV-1-infected target cells and the disease progression status of HIV-1-infected individuals. The contribution of NKG2D to NK cell-mediated anti-HIV-1 antibody-dependent activation and/or cytolysis has not yet been determined. We hypothesized that a collaborative relationship between NKG2D and CD16 could exist that determines the potency of anti-HIV-1 antibody-dependent NK cell responses. This could be instrumental in understanding HIV-1 pathogenesis and instructive for designing an HIV-1 vaccine and/or therapeutic utilizing anti-HIV-1 ADCC. As such, we assessed the contribution of NKG2D to anti-HIV-1 envelope glycoprotein (Env) ADCC. The presented data suggest NKG2D collaborates with CD16 to enhance NK cell-mediated antibody-dependent responses against HIV-1 gp120-coated and HIV-1-infected T-cell line targets.
Materials and Methods
Subjects
Blood was obtained from 22 HIV-1-uninfected donors by forearm venipuncture into vacuettes containing sodium heparin anticoagulant. Peripheral blood mononuclear cells (PBMC) were enriched from blood via the Ficoll-Hypaque density gradient. These PBMC were used as effector cells in cytolysis assays or to enrich primary NK effector cells for some renditions of the lactate dehydrogenase (LDH) release assay. All donors provided informed consent before sample collection, and all participating institutions approved the described studies.
Anti-HIV-1 antibodies and cell lines
The CEM.NKr-CCR5 cell line (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) was used as target cells in the anti-HIV-1 ADCC LDH release and flow cytometrybased cytolysis assays. The A32 monoclonal antibody and the polyclonal HIV immunoglobulin (HIVIG) (both from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) were used to induce anti-HIV-1 ADCC in the flow cytometry-based and LDH release cytolysis assays, respectively.
Enrichment of primary NK cells from PBMC
Enrichment of NK cells was performed, according to the manufacturer's protocol, using an NK cell enrichment kit (StemCell Technologies). Purity of enriched NK cells was assessed by flow cytometry. Pre-and post-enrichment cell populations were stained with anti-CD3 (Clone: SK7; Per-CP conjugated; BD) and anti-CD56 (Clone: NCAM 16.2; PECy7 conjugated; BD) antibodies. After staining, cells were fixed with 1% formaldehyde and acquired using an LSR Fortessa flow cytometer (BD). Data were analyzed with FlowJo software (Treestar).
Lactate dehydrogenase release cytolysis assay
The LDH release cytolysis assay for ADCC detection was performed as previously described. 12 To measure anti-HIV-1 ADCC by LDH release, we utilized the Cytotox 96 Ò Non-Radioactive Cytotoxicity Assay Kit (Promega). The CEM.NKr-CCR5 target cells were prepared by pulsing with HIV-1 Bal gp120 (3 lg/ml) (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) for 90 min at 4°C. Effector cells consisted of freshly isolated PBMC or enriched NK cells. All assay conditions were conducted in triplicate in 96-well round-bottomed plates (Greiner Bio-One). The maximum LDH release of target cells was determined by the addition of lysis solution (Promega) to wells containing only target cells for the last 45 min of the assay. The spontaneous release of LDH from both targets and effectors was assessed using wells containing either cell population alone. For experimental and control conditions, effector and target cells were combined at 25:1 (5 · 10 5 effectors + 2 · 10 4 targets) and 10:1 (2 · 10 5 effectors + 2 · 10 4 targets) ratios. The experimental conditions measured the LDH released on coincubation of PBMC, or enriched NK cells, with gp120-pulsed CEM.NKr-CCR5 and a 1:2,000 dilution of HIVIG. Control conditions measured LDH released on incubations of PBMC and gp120-pulsed CEM.NKr-CCR5 cells in the absence of antibody. To assess the role of NKG2D in the anti-HIV-1 ADCC observed, additional experimental conditions were conducted containing 5 lg/ml of an anti-NKG2D antibody capable of blocking NK cell activation through NKG2D (Clone: 1D11; BioLegend), or 5 lg/ml of an isotype control antibody (Clone: MOPC-21; BioLegend). 24 A series of additional control wells containing media only were also set up. Next, plates were spun for 4 min at 250 · g and incubated for 4 h at 37°C. After 3 h and 15 min, the lysis solution was added to the maximum target release wells and plates were 1090 PARSONS ET AL.
incubated for a further 45 min at 37°C. After the complete 4-h incubation, plates were spun for 4 min at 250 · g. Next, fifty microliters of supernatant was removed from each well and transferred to an ELISA plate. Following transfer of supernatants to the ELISA plates, 50 ll of substrate (Promega) was added to each well containing a supernatant and incubated for 30 min at room temperature in the dark. Finally, 50 ll of stop solution was added to each well and absorbance was read at 492 nm. The optical density values for wells containing media only were subtracted from all other wells. The remaining values were used to calculate the percent cytotoxicity using the following formula: % cytotoxicity = [(experimental -effector spontaneous -target spontaneous)/(target maximumtarget spontaneous)] · 100.
HIV-1-infection of CEM.NKr-CCR5 cells
CEM.NKr-CCR5 cells were infected with vesicular stomatitis virus G (VSVG)-pseudotyped NL4.3 green fluorescent protein (GFP) expressing ADA Env-based viruses that carried wild-type or defective Vpu and Nef genes (U-N-). Infection was accomplished by spin inoculation at 800 · g for 1 h in 96-well plates at 25°C. After a 48-h period postinfection, these cells were utilized as target cells in the flow cytometry-based cytolysis assay and for detection of NKG2D ligand expression. An average of 11.8% and 10.7% of cells were infected with the wild-type and U-N-viruses, respectively.
Detection of NKG2D ligand expression on CEM.NKr-CCR5 cells
To assess the expression of NKG2D ligands on HIV-1-uninfected or HIV-1-infected CEM.NKr-CCR5 cells, we treated cells with a NKG2D-Fc fusion protein (R&D Systems) and detected binding with an Alexa-Fluor-647-conjugated goat anti-human IgG antibody (Invitrogen). Data were collected on an LSR II flow cytometer (BD) and analyzed on FlowJo software (Treestar).
Flow cytometry-based cytolysis assay
The flow cytometry-based ADCC assay was conducted as previously described. 25, 26 Briefly, CEM.NKr-CCR5 targets infected with wild type or U-N-HIV-1 were stained with the AquaVivid viability (Invitrogen) and cellular marker eFluor670 (eBiosciences) dyes. The PBMC effectors were stained with the cellular marker eFluor 450 dye (eBiosciences). Next, effectors and targets were combined at a 10:1 ratio in V-bottomed 96-well plates (Corning) in the presence or absence of the A32 anti-HIV-1 monoclonal antibody (5 lg/ml). To assess the role of NKG2D in the A32-mediated ADCC of HIV-1-infected CD4 + T cells, conditions were conducted in which an anti-NKG2D antibody (10 lg/ml, Clone: 1D11; BioLegend) or an isotype control antibody (Clone: MOPC-21; BioLegend) was added. These combinations of effectors, targets, and antibodies were incubated at room temperature for 15 min, which was followed by a 1-min spin at 300 · g and a 6-h incubation at 37°C. After the incubation, cells were fixed with a 2% formaldehyde solution containing flow cytometry particles (5 · 10 
Statistics
The significance of differences between paired and unpaired data sets was analyzed with the Wilcoxon matchedpairs signed rank and Mann-Whitney tests, respectively. The significance of differences between three paired data sets was analyzed using the
Results
Role of NKG2D in HIV-1-specific ADCC of gp120-pulsed CEM.NKr-CCR5 target cells
To assess the role of NKG2D in anti-HIV-1 ADCC, we investigated if ligation of NKG2D was involved in the ADCC of gp120-pulsed CEM.NKr-CCR5 target cells. To measure anti-HIV-1 ADCC, we implemented the LDH release cytolysis assay, as previously described. 12 The LDH release assay readily detects anti-HIV-1 ADCC of gp120-pulsed CEM.NKr-CCR5 target cells by effector cells within PBMC in the presence of HIVIG (Fig. 1) . To assess the contribution of NKG2D to anti-HIV-1 ADCC, we implemented conditions containing anti-NKG2D blocking or isotype control antibodies in addition to PBMC effectors, gp120-pulsed CEM.NKr-CCR5 target cells, and HIVIG. As depicted in Figure 1 , at both 25:1 and 10:1 effector to target cell ratios, the anti-NKG2D antibody reduced observed ADCC [25:1-29 05 ). These data imply that ligation of NKG2D contributes to the anti-HIV-1 ADCC of gp120-pulsed CEM.NKr-CCR5 target cells, as the background lysis of CEM.NKr-CCR5 targets in the absence of HIVIG (25:1-median: 2.6%; 10:1-median: 0.5%) was too small to account for the observed effect of NKG2D blocking. As we had observed a role for NKG2D in the anti-HIV-1 ADCC of gp120-pulsed CEM.NKr-CCR5 target cells, we next investigated if NKG2D contributed to the elimination of HIV-1-infected CEM.NKr-CCR5 cells by ADCC. Previous research has demonstrated that HIV-1 Vpu and Nef downregulate cell surface CD4 on HIV-1-infected cells, which prevents viral envelope from entering into the CD4-bound conformation. 26 This phenomenon allows HIV-1-infected cells to evade anti-HIV-1 Env ADCC, as ADCC-competent anti-HIV-1 antibodies in patients primarily target epitopes revealed in the CD4-bound envelope conformation. 26, 27 As such, to investigate the potential role of NKG2D in the anti-HIV-1 ADCC of infected T cells, we utilized CEM.NKr-CCR5 target cells infected with either wild-type HIV-1 or U-N-HIV-1 and assessed the ability of PBMC effectors to kill these targets through utilization of the A32 anti-HIV-1 monoclonal antibody, which is an ADCC-mediating monoclonal antibody that best recognizes the CD4-bound conformation of envelope. 26, 28, 29 Before measuring anti-HIV-1 ADCC, we assessed target cells infected with wild-type or U-N-HIV-1 for expression of NKG2D ligands and binding of the A32 antibody. Utilizing the NKG2D-Fc fusion protein, we detected expression of NKG2D ligands on cells not infected with HIV-1 or infected with either wild-type or U-N-viruses (Fig. 3A) . Similar to previously reported data suggesting Nef can downregulate NKG2D ligands on HIV-1-infected T-cell lines, expression of NKG2D ligands was lower on T cells infected with wildtype HIV-1, compared to cells infected with U-N-HIV-1 ( p = .0006) (Mann-Whitney test) (Fig. 3A) . 20 Also, reflective of previously reported data, we primarily detected A32 binding on cells infected with U-N-virus ( p = .0006) (MannWhitney test) (Fig. 3B) . 26, 30 To measure anti-HIV-1 ADCC of HIV-1-infected targets, we implemented a flow cytometry-based cytolysis assay that measures the loss of viable HIV-1-infected target cells, as previous described. 25, 26 As expected from the A32 binding data, A32-mediated ADCC was consistently observed against cells infected with U-N-deficient HIV-1, but not against those infected with wild-type HIV-1 (Fig. 3C Middle graph vs. Left graph). To determine if NKG2D signals were contributing to the observed ADCC, we implemented conditions in which target cells, PBMC effectors, and A32 monoclonal antibodies were coincubated with the anti-NKG2D antibody or an isotype control. As depicted in Figure 3C of several activating NK cell receptors, including NKG2D, can act synergistically with signals through CD16 to enhance NK cell calcium flux. 15 The data in the present article build on this observation through demonstrating that ligation of NKG2D contributes to anti-HIV-1 ADCC. A role for NKG2D was observed for anti-HIV-1 ADCC against both gp120-pulsed and HIV-1-infected CEM.NKr-CCR5 targets. These observations have potential ramifications for optimizing vaccinations and/or therapeutics utilizing ADCC and/ or other antibody-dependent NK cell-mediated effector functions.
Although the data presented in the current article demonstrate a role for NKG2D in the anti-HIV-1 ADCC of target cells infected with HIV-1, it should be noted that due to the inability to detect ADCC against cells infected with wildtype HIV-1, a role for NKG2D could only be demonstrated against cells infected with U-N-HIV-1. As such, the role NKG2D might play in ADCC against cells infected with wild-type HIV-1 remains unknown. It has previously been reported that Nef downregulates NKG2D ligands from the surface of HIV-1-infected T-cell lines. 20 Importantly, the capacity of Nef to downregulate NKG2D ligands was not observed in primary T cells infected with HIV-1. 31 The reason(s) for these conflicting results should be addressed in future studies. The data in the current article, however, corroborate the observation that Nef downregulates NKG2D ligands in HIV-1-infected T-cell lines, as we consistently observed lower mean fluorescence intensity for the binding of shown to be susceptible to direct NK cell-mediated lysis via NKG2D signaling, we predict that the levels of NKG2D on the surface of T cells infected with wild-type HIV-1 will be sufficient to contribute to anti-HIV-1 ADCC. 32 Future experiments to investigate this issue should be possible, given the recent demonstration that certain CD4 mimetics can open cell surface HIV-1 envelope into the CD4-bound conformation and make ADCC epitopes accessible to antibodies. 30 These CD4 mimetics have great therapeutic potential for ''shock and kill'' strategies that wish to utilize ADCC to eliminate HIV-1-infected cells, and an extensive knowledge of other NK cell receptors that could contribute to anti-HIV-1 ADCC might be important for optimization of such antilatency approaches. 33, 34 The observation that NKG2D contributes to ADCC mediated by NK cells also draws attention to previous studies demonstrating the MMP-induced release of soluble NKG2D ligands by HIV-1-infected target cells. 23 These soluble ligands bind to NK cell or T-cell surface NKG2D and induce downregulation of the activating receptor, leading to poorer antibody-independent responses. Given our observation that NKG2D not only contributes to direct NK cell functions but also plays a role in antibody-dependent functions, we predict that soluble NKG2D ligands might also impede the ability of NK cells to mediate robust antibody-dependent responses. Future studies should investigate this possibility by assessing NK cell-mediated ADCC against HIV-1-infected cells that release soluble NKG2D ligands. In addition to cleaving NKG2D ligands from the surface of target cells, MMPs are involved in cleaving CD16 from the surface of NK cells post-activation. [35] [36] [37] [38] Furthermore, inhibition of MMPs in cultures of NK cells and antibody-coated target cells improves the ability of NK cells to function. 39 Future research should further investigate the prospect of specifically targeting MMPs to improve the ability of NK cells to utilize therapeutic antibodies.
Future research should also investigate the role of NKG2D in ADCC mediated by NK cells obtained from HIV-1-infected donors. Indeed, viremic HIV-1 infection is characterized by alterations to the NK cell population, including the development of a hypofunctional CD56 -CD16 + subset. 40 HIV-1-infected donors who are coinfected with CMV also exhibit an exaggerated development of a CD57 + NKG2C + NK cell subset, which normally arises during CMV infection. 41 In CMV-infected donors, these NK cells exhibit more robust CD16-dependent stimulation than NKG2C
-NK cells. 42 The relative utilization of NKG2D or other ADCC coreceptors by NK cells from HIV-1-infected donors represents important information for optimizing the application of therapeutic antibodies in these individuals.
There is much interest in utilizing non-neutralizing antibody effector functions, such as ADCC, to target HIV-1 via vaccination or to eliminate latently infected cells that have been reactivated. 43, 44 The data in the present article reveal that these NK cell-mediated antibody-dependent responses are not only solely mediated through the CD16 Fc receptor but also depend on ligation of an antibody-independent activating receptor, NKG2D. Future experiments assessing how the role of NKG2D in anti-HIV-1 antibody-dependent NK cell functions can be utilized to augment these responses will be helpful in improving the efficacy of antibody-based vaccines and/or therapeutics.
